| HUO Xiao-dong,ZHENG Guang-jun,CHAI Shu-de,et al.Clinical efficacy of CT-guided 125I radioactive seeds implantation for stage Ⅲ of non-small cell lung cancer[J].Chinese Journal of Radiological Medicine and Protection,2012,32(2):199-203 |
| Clinical efficacy of CT-guided 125I radioactive seeds implantation for stage Ⅲ of non-small cell lung cancer |
| Received:June 08, 2011 |
| DOI：10.3760/cma.j.issn.0254-5098.2012.02.023 |
| KeyWords:125I|Non-small cell lung cancer(NSCLC)|Curative effect analysis |
| FundProject: |
|
| Hits: 4832 |
| Download times: 2760 |
| Abstract:: |
| Objective To evaluate the clinical effects of CT-guided 125I radioactive seed implantation in treatment of stage Ⅲ non-small cell lung cancer (NSCLC) and the influential factors of prognosis. Methods 247 patients of stage Ⅲa/Ⅲb NSCLC underwent CT-guided 125I radioactive seed implantation.The clinical effects and the factors affecting prognosis were analyzed by univariate and multivariate analyses. Results The 1-, 3-, and 5- year overall survival rates were 82.8%, 23.8%, and 11.5%, respectively. The median survival time was 24.8 months, and the local control rate was 92.2%, 63.8％, and 25.7%, respectively. The 5- year overall survival rate was 14.7％,and the median survival time was 29.7 months of the stage Ⅲa patients. And the 5- year overall survival rate was 11.2％,and the median survival time was 24.0 months at the stage Ⅲb. Univariate analysis showed that age, course of disease, hemoglobin before treatment, clinical stage, maximum diameter of tumor, prescribed dose (PD), post-operational mean dose, post-operational dose covering 100% volume (D100), remedial model were the main prognostic factors; however, multivariate analysis revealed that hemoglobin ≥120 g/L before treatment, post-operational dose covering 100% volume (D100) and maximum diameter of tumor were the independent risk factors for predicting the survival. Aerothorax was observed in 37 patients with an incidence rate of 14.9%, and hemothorax was observed in 22 patients with an incidence rate of 9%. Conclusions 125I radioactive seed implantation therapy is effective in the treatment of stage Ⅲ NSCLC. Hemoglobin level before treatment, post-operational dose covering 100% volume (D100), and maximum diameter of tumor are the main prognostic factors for the NSCLC patients treated with radiotherapy for NSCLC. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
